Liminatus Pharma ( (LIMN) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma, a pharmaceutical company, has filed a Form 12b-25 indicating a delay in submitting its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the inability to complete financial statements in time for necessary reviews and signatures before the due date. The company anticipates filing the report within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the corresponding period of the previous fiscal year, and forward-looking statements have been noted. Liminatus Pharma continues to work on compliance efforts, with the notification signed by CEO Chris Kim.
More about Liminatus Pharma
Average Trading Volume: 616,420
Technical Sentiment Signal: Sell
Current Market Cap: $111.5M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.